The positive X-TOLE2 data and near-term NDA submission are the primary catalysts, but the revenue decline and increased losses temper the bullish case. Traders should monitor enrollment updates for X-TOLE3 and X-ACKT studies, and any regulatory feedback ahead of the NDA filing.
XENE drugs
XENE drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 8 $56.44entry
- T+1 · 6mo ago −1.17%α −1.40% · $55.78
- T+5 · 6mo ago −0.78%α −2.24% · $56.00
- T+20 · 5mo ago −8.35%α −8.37% · $51.73
- T+60 · 3mo ago +13.41%α +8.57% · $64.01
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Xenon Pharmaceuticals reported Q1 2026 net loss of $102.3M ($1.17/share) vs $65.0M ($0.83/share) in Q1 2025, with zero revenue compared to $7.5M a year ago. The miss is overshadowed by positive Phase 3 X-TOLE2 data for azetukalner in focal onset seizures, with an NDA submission expected in Q3 2026 and a strong cash position of $1.34B funding operations into 2029.
Key Financial Metrics
Key Facts
- Phase 3 X-TOLE2 study met primary endpoint with placebo-adjusted median percent change in seizure frequency of -42.7% (25 mg dose), the highest ever observed in a pivotal FOS study.
- NDA submission for azetukalner in focal onset seizures planned for Q3 2026.
- Cash, cash equivalents and marketable securities of $1,339.6 million as of March 31, 2026, up from $586.0 million at year-end 2025.
- Net loss increased to $102.3 million in Q1 2026 from $65.0 million in Q1 2025, driven by higher R&D spend and zero collaboration revenue.
- Research and development expenses rose to $88.5 million from $61.2 million year-over-year.
Financial Impact
Net loss of $102.3M in Q1 2026, up from $65.0M in Q1 2025; revenue declined from $7.5M to $0.
Risk Factors
- Regulatory delays or negative FDA review of the NDA for azetukalner.
- Clinical trial setbacks in ongoing Phase 3 studies for MDD, BPD, or PGTCS.
- Dilution risk from continued use of ATM or follow-on offerings despite strong cash position.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3290503 |
Track record
19 reports on XENE
3 of 5 bullish or bearish reports moved the stock their way by T+1. Best: +18.60% at T+60 after the Apr 19, 2026 report. 4 of 5 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $40.11 Now $39.26 −2.12% settles Nov 17
- Nov 9, 20267d ago 8-K Neutral 5/10 Entry $41.39 to $42.10 Now $39.26 −5.15% ▲ +1.72% +0.40% vs SPY
- Nov 6, 202610d ago SC 13G/A Neutral 2/10 Entry $39.17 to $40.45 Now $39.26 +0.23% ▲ +3.27% +0.90% vs SPY
- Nov 6, 202610d ago SC 13G Neutral 4/10 Entry $39.17 to $40.45 Now $39.26 +0.23% ▲ +3.27% +0.90% vs SPY
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $37.68 to $39.17 Now $39.26 +4.19% ▲ +3.95% +3.64% vs SPY
- Nov 3, 202613d ago Press Release Neutral 2/10 Entry $39.19 to $37.68 Now $39.26 +0.18% ▼ −3.85% +0.56% vs SPY
- Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $38.23 to $39.19 Now $39.26 +2.69% ▲ +2.51% +0.86% vs SPY
- Oct 1, 20266w ago Insider Cluster Bullish 6/10 Entry $38.93 to $38.02 Now $39.26 +0.85% ▼ −2.34% −3.08% vs SPY
- Jul 2, 202619w ago Press Release Neutral 1/10 Entry $60.96 to $60.54 Now $39.26 −35.60% ▼ −0.69% −1.56% vs SPY
- Jun 5, 202623w ago 144 Neutral 2/10 Entry $51.21 to $52.79 Now $39.26 −23.34% ▲ +3.09% +3.38% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers